| Literature DB >> 31741615 |
Pavan Reddy1, Ramesh Shankar2, Teena Koshy3, Venkatraman Radhakrishnan1, Prasanth Ganesan1, P K Jayachandran1, Manikandan Dhanushkodi1, Nikita Mehra1, S Krupashankar1, P Manasa2, R P Nagare2, R Swaminathan4, Krishnarathinam Kannan1, T G Sagar1, T S Ganesan1.
Abstract
Acute lymphoblastic leukemia (ALL) accounts for 20% of all adult leukemias and is the most common leukemia during childhood (80%). We present data on cytogenetics of ALL from a tertiary centre in India correlating it with clinical factors. Karyotyping of bone marrow samples of 204 patients with newly diagnosed ALL was performed with standard G-banding technique. Clinical data of patients was obtained from case records. Survival was estimated using Kaplan-Meir curves and compared by the log-rank test. Univariate and multivariate analysis was done for survival with age, sex, immunophenotype, hyperleukocytosis, risk type, remission status and cytogenetics. The most common karyotypes observed were normal in 39.7% (N = 81), hyperdiploidy in 12.7% (N = 26), t(9;22) in 4.4% (N = 9), t(1;19) in 3.9% (N = 8). Adults with ALL had worse survival compared with pediatric patients (HR 3.62; 2.03-6.45 95% CI, p < 0.001). Patients not in morphologic remission after induction chemotherapy fared poorly (HR 4.86; 2.67-8.84 95% CI, p < 0.001). Patients with favourable cytogenetics had better overall survival (HR 0.36; 0.12-1.05 95% CI, p < 0.05). On multivariate analysis, achievement of morphologic remission emerged as single most significant predictor of survival (p < 0.001). MLL gene rearrangement and t(12;21) were seen less commonly as compared to Western data. However, incidence rates of various cytogenetic abnormalities were similar to that reported from other centres from India. Age, morphologic remission at end of induction chemotherapy and favourable cytogenetics correlated significantly with survival. © Indian Society of Hematology and Blood Transfusion 2019.Entities:
Keywords: Acute lymphoblastic leukemia; Cytogenetics; India; Karyotype; Overall survival
Year: 2019 PMID: 31741615 PMCID: PMC6825071 DOI: 10.1007/s12288-019-01123-8
Source DB: PubMed Journal: Indian J Hematol Blood Transfus ISSN: 0971-4502 Impact factor: 0.900